Fezolinetant as a New Treatment for Menopausal Symptoms
Monograph
Are you a Pharmacy Tech? Check out the Pharmacy Tech version of this course.
Course Summary
Many women experience menopausal vasomotor symptoms such as hot flashes and night sweats during menopause. Their severity can vary greatly, with some women suffering significant symptoms that impact their quality of life. Fezolinetant was approved in May 2023 as a new treatment option for menopausal vasomotor symptoms. It regulates body temperature by interacting with neurokinin-3 receptors. For some patients, fezolinetant may provide another treatment option to relieve menopausal symptoms. By understanding the incidence, risk factors, and genetic influences related to hot flashes and night sweats, healthcare teams can effectively identify and manage these symptoms in menopausal women. In this course, pharmacists and pharmacy technicians are introduced to the use, effectiveness, and potential side effects of fezolinetant.
Course Objectives
Describe the pharmacology of fezolinetant for treating menopausal vasomotor symptoms
Evaluate the clinical evidence supporting the effectiveness and safety of fezolinetant in reducing the frequency and severity of menopausal vasomotor symptoms
Describe fezolinetant’s potential drug interactions and adverse effects.
Learn patient counseling for the safe use of fezolinetant in managing menopausal vasomotor symptoms
- Introduction
- Epidemiology: Prevalence and Risk Factors
- Management of Vasomotor Symptoms
- Mild Symptoms: Lifestyle Modifications
- Moderate to Severe Symptoms
- Fezolinetant as an Option for Managing Vasomotor Symptoms
- Clinical Trials
- Mechanism of Action
- Indications
- Dosing
- Contraindications and Warnings
- Side Effects or Adverse Events
- Drug-Drug Interactions
- Handling and Storage
- Patient Counseling
- Interdisciplinary Approach and Collaboration
- Summary
- Read the course objectives and faculty planner disclosure
- Read the course material
- Complete the post-test with a minimum score of 70% and complete the course evaluation form.
- Results are automatically submitted to CPE Monitor
Faculty Planner Disclosure
The following individuals were involved in developing this activity: Steven Malen, PharmD, MBA, and Pamela Sardo, PharmD, BS. Pamela Sardo, Pharm.D., B.S., was an employee of Rhythm Pharmaceuticals until March 2022 and has no conflicts of interest or relationships regarding the subject matter discussed. There are no financial relationships relevant to this activity to report or disclose by any of the individuals involved in the development of this activity.
Unlabeled Use Disclosures
The information provided in this course is general in nature and it is solely designed to provide participants with continuing education credit(s). This course and materials are not meant to substitute for the independent, professional judgment of any participant regarding that participant’s professional practice, including but not limited to patient assessment, diagnosis, treatment and/or health management. Medical and pharmacy practices, rules, and laws vary from state to state, and this course does not cover the laws of each state; therefore, participants must consult the laws of their state as they relate to their professional practice. Healthcare professionals, including pharmacists and pharmacy technicians, must consult with their employer, healthcare facility, hospital, or other organization, for guidelines, protocols, and procedures they are to follow. The information provided in this course does not replace those guidelines, protocols, and procedures but is for academic purposes only, and this course’s limited purpose is for the completion of continuing education credits. Participants are advised and acknowledge that information related to medications, their administration, dosing, contraindications, adverse reactions, interactions, warnings, precautions, or accepted uses are constantly changing, and any person taking this course understands that such person must make an independent review of medication information prior to any patient assessment, diagnosis, treatment and/or health management. Any discussion of off-label use of any medication, device, or procedure is informational only and such uses are not endorsed hereby. Nothing contained in this course represents the opinions, views, judgments, or conclusions of RxCe.com LLC. RxCe.com LLC is not liable or responsible to any person for any inaccuracy, error, or omission with respect to this course, or course material.
Computer Hardware/Software Requirements
Please ensure the device you plan to use meets these requirements and specifications:
- Operating System: Windows 7,8,10, or 11 /Mac OS X 10.9 or later/iOS/Android
- Supported Browsers: Microsoft Edge, Firefox, Google Chrome, Safari, Opera
- A connection to the internet
- For Live Webinars or Conferences: GoToWebinar application for iOS, Android, Mac, or PC. You cannot 'call into' a live conference.
- Target Audience: Pharmacist
- Contact Hours: 1.0 (0.1 CEUs)
- Activity Release Date: 7/8/2023
- Activity Expiration Date: 7/8/2026
- Activity Type: Knowledge
- UAN: 0669-0000-23-102-H01-P
- Topic: Disease State Management/Drug Therapy
- CeBroker Number: 20-1084728
Author:
RxCe.com, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.